Drug Profile
Prourokinase recombinant - Tasly Pharmaceutical
Alternative Names: B-1140; B-1448; Pro-UK; PUK; Recombinant human pro-urokinase; Recombinant human urokinase - Tasly Pharmaceuticals; rhPro-UK; rhPro-uk - Tasly PharmaceuticalsLatest Information Update: 24 Feb 2023
Price :
$50
*
At a glance
- Originator Tasly Pharmaceuticals, Inc.
- Class Anti-ischaemics; Plasminogen activator enzymes; Thrombolytics; Vascular disorder therapies
- Mechanism of Action Plasminogen activators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Myocardial infarction
- Preregistration Pulmonary embolism
- Phase III Stroke
Most Recent Events
- 29 Jan 2023 Tasly Biopharmaceuticals initiates a phase III PROST-2 trial for Stroke in China (IV, Infusion) (NCT05700591)
- 26 Jan 2023 Tasly Biopharmaceuticals plans a phase III PROST-2 trial for Stroke (IV, Infusion) in February 2023 (NCT05700591)
- 12 Jul 2022 Preregistration for Pulmonary embolism in China (IV), before July 2022 (Tasly Pharmaceutical pipeline, July 2022)